Abstract
Background
Recent growth in the functionality and use of technology has prompted an increased interest in the potential for remote or decentralised clinical trials in dementia. There are many potential benefits associated with decentralised medication trials, but the field is currently lacking specific recommendations for their delivery in the dementia field.
Method
A modified Delphi method engaged a panel with substantial expertise in dementia trial design and delivery and backgrounds that included neurology, psychiatry, pharmacology and psychology, to develop recommendations for the conduct of decentralised medication trials in dementia prevention. A working group of researchers and clinicians with expertise in dementia trials further refined the recommendations.
Result
Overall, the recommendations support the delivery of decentralised remote trials in dementia prevention provided adequate safety checks and balances are included. A total of 40 recommendations will be presented, spanning aspects of decentralised clinical trials dementia prevention trials in phases 2b-4, including safety, dispensing, outcome assessment, and data collection.
Conclusion
With these recommendations we provide an accessible, pragmatic guide for the design and conduct of remote medication trials for the prevention of dementia.
Recent growth in the functionality and use of technology has prompted an increased interest in the potential for remote or decentralised clinical trials in dementia. There are many potential benefits associated with decentralised medication trials, but the field is currently lacking specific recommendations for their delivery in the dementia field.
Method
A modified Delphi method engaged a panel with substantial expertise in dementia trial design and delivery and backgrounds that included neurology, psychiatry, pharmacology and psychology, to develop recommendations for the conduct of decentralised medication trials in dementia prevention. A working group of researchers and clinicians with expertise in dementia trials further refined the recommendations.
Result
Overall, the recommendations support the delivery of decentralised remote trials in dementia prevention provided adequate safety checks and balances are included. A total of 40 recommendations will be presented, spanning aspects of decentralised clinical trials dementia prevention trials in phases 2b-4, including safety, dispensing, outcome assessment, and data collection.
Conclusion
With these recommendations we provide an accessible, pragmatic guide for the design and conduct of remote medication trials for the prevention of dementia.
| Original language | English |
|---|---|
| Pages | e085781 |
| Number of pages | 1 |
| DOIs | |
| Publication status | Published - 9 Jan 2025 |
| Event | AAIC 2024: Alzheimer’s Association International Conference 2024 - Philadelphia, United States Duration: 28 Jul 2024 → 1 Aug 2024 https://aaic.alz.org/highlights2024.asp |
Conference
| Conference | AAIC 2024: Alzheimer’s Association International Conference 2024 |
|---|---|
| Country/Territory | United States |
| City | Philadelphia |
| Period | 28/07/24 → 1/08/24 |
| Internet address |
Bibliographical note
© 2024 The Alzheimer's Association. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.Keywords
- Humans
- Dementia/prevention & control
- Drug Development
- Clinical Trials as Topic
- Delphi Technique
- Research Design